Synergistic anticancer effects of camptothecin and sotorasib in KRAS-mutated pancreatic ductal adenocarcinoma

BackgroundSotorasib (AMG510) is a first-in-class irreversible, covalent, and selective KRAS G12C inhibitor. However, in patients, acquired clinical resistance was observed within 1 year of its FDA approval. Researchers are exploring combination and repurposing strategies to help overcome this resist...

Cijeli opis

Bibliografski detalji

Glavni autori:	Prasanna Srinivasan Ramalingam, Gayathri Chellasamy, Md Sadique Hussain, Gothandam Kodiveri Muthukaliannan, Tajamul Hussain, Salman Alrokayan, Kyusik Yun, Janaki Ramaiah Mekala, Sivakumar Arumugam
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2025-07-01
Serija:	Frontiers in Pharmacology
Teme:	alkaloid camptothecin sotorasib KRAS mutation PDAC synergistic effect
Online pristup:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1635449/full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!